Bahrain on Wednesday approved the emergency use for REGN-COV2 medicine, Regeneron Pharmaceuticals Inc’s and Roche’s newly authorized COVID-19 antibody combination, as part of its coronavirus treatment protocol to treat existing cases with mild and moderate symptoms.
REGN-COV2 contains a combination of Casirivimab and Imdevimab, which are drugs called “monoclonal antibodies”, that are designed to block viral attachment and entry into human cells to neutralize the virus, state news agency (BNA) reported.
The report said updating the corona treatment protocol in the kingdom would reduce symptoms complications.
